Amneal Pharmaceuticals (NASDAQ:AMRX) Raised to “Strong-Buy” at Wall Street Zen

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday.

A number of other research firms have also weighed in on AMRX. Barclays boosted their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. UBS Group began coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.80.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $16.21 on Friday. The stock has a market cap of $5.17 billion, a PE ratio of 42.66 and a beta of 1.30. The company’s fifty day moving average is $13.41 and its 200 day moving average is $13.23. Amneal Pharmaceuticals has a 52 week low of $7.66 and a 52 week high of $16.61.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The business had revenue of $722.52 million during the quarter. Sell-side analysts anticipate that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Oliver Luxxe Assets LLC purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $1,972,000. Artemis Investment Management LLP purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $1,574,000. Envestnet Asset Management Inc. bought a new position in Amneal Pharmaceuticals during the 3rd quarter valued at approximately $1,608,000. Citigroup Inc. increased its position in Amneal Pharmaceuticals by 55.7% during the 3rd quarter. Citigroup Inc. now owns 282,862 shares of the company’s stock valued at $2,831,000 after buying an additional 101,166 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Amneal Pharmaceuticals by 2,866.0% during the fourth quarter. SG Americas Securities LLC now owns 784,803 shares of the company’s stock valued at $9,889,000 after buying an additional 758,343 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.